Parkinson's Disease Program(s)

About Tanabe Pharma America

Tanabe Pharma America is a U.S.-based pharmaceutical company established in 2017 as the American arm of the long-standing Japanese firm Tanabe Pharma Corporation. The company is in the commercial and late-stage clinical development stage, with a marketed product for ALS (RADICAVA/edaravone, recently transferred) and a late-phase pipeline asset, dersimelagon, for rare photodermatoses. TPA's strategy centers on advancing small molecule therapies for severe neurological and rare diseases, building on its parent company's extensive R&D heritage. It operates as a private, revenue-generating entity, though specific financials are not disclosed.

Therapeutic Areas

Other Parkinson's Disease Drugs